Last reviewed · How we verify
NCT05293873
Outcomes of Autologous Bone Marrow-derived Mononuclear Cell Transplantation in the Management of Neurological Sequelae
Phase 1, PHASE2 trial testing autologous bone marrow-derived mononuclear cell transplantation in Sequelae of Injuries of Head in 50 participants. Completed in 30 June 2023.
30 March 2023
Quick facts
| Lead sponsor | Vinmec Research Institute of Stem Cell and Gene Technology |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 April 2021 |
| Primary completion | 30 March 2023 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across Vietnam |
Drugs / interventions tested
- autologous bone marrow-derived mononuclear cell transplantation — full drug profile →
- Rehabilitation therapy
Conditions studied
- Sequelae of Injuries of Head — all drugs for Sequelae of Injuries of Head →
Sponsor
Vinmec Research Institute of Stem Cell and Gene Technology
Who can join
Adults 20 to 50, any sex, with Sequelae of Injuries of Head. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow-derived mononuclear cell transplantation in the management of neurological sequelae after traumatic brain injury
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Backpack-mediated anti-inflammatory macrophage cell therapy for the treatment of traumatic brain injury.
Kapate N, Liao R, Sodemann RL, Stinson T, et al · · 2024 · cited 16× · PMID 38187808 · DOI 10.1093/pnasnexus/pgad434 -
Autologous bone marrow mononuclear cell administration for neurological sequelae after traumatic brain injury: a matched control study.
Nguyen LT, Thi Huong Ha G, Trung Nguyen K, Thanh Hoang V, et al · · 2025 · PMID 41063968 · DOI 10.1093/braincomms/fcaf361
Verify or expand the search:
- PubMed search for NCT05293873
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Vinmec Research Institute of Stem Cell and Gene Technology trials
Trials by the same sponsor.
- NCT07472270 — Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment · Phase 1 · not yet recruiting
- NCT06629324 — Evaluating Bone Marrow Cell Transplant for Treating Cerebral Palsy From Brain Hypoxia · Phase 2 · recruiting
- NCT06726538 — Investigating the Efficacy of Autologous, Adipose-derived Mesenchymal Stem Cell Therapy for the Treatment of Sexual Func · Phase 1, PHASE2 · completed
- NCT06027957 — CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia · Phase 1 · completed
- NCT05329662 — Adipose Tissue-derived Mesenchymal Stem Cell (AD-MSC) Therapy for the Treatment of Sexual Function Impairment in Female · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05293873 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vinmec Research Institute of Stem Cell and Gene Technology
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05293873.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing